SCHEMBL25359682

SCHEMBL25359682

CC(=O)c1cc(C)cc2c(=O)n(C)c(-c3ccccc3)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 5/20 0.45
EGFR P00533 1/20 0.42
BRD4 O60885 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ADORA2A P29274 1/20 0.40
ADORA2B P29275 1/20 0.40
BCL2 P10415 2/20 0.39
MCL1 Q07820 2/20 0.39
PARG Q86W56 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
TLR7 Q9NYK1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30690313 1.00 DHODH (0.45) DHODHEGFRBRD4KDM4EALDH1A1
SCHEMBL30690356 0.89 HTT (0.37) DHODHKDM4EALDH1A1TDP1MAPT
SCHEMBL29139169 0.89 HTT (0.37) DHODHKDM4EALDH1A1TDP1MAPT
SCHEMBL25359989 0.88 DHODH (0.38) DHODHL3MBTL1
SCHEMBL30495146 0.88 DHODH (0.38) DHODHL3MBTL1
SCHEMBL30495268 0.88 EGFR (0.48) DHODHEGFRBRD4KDM4EADORA2A
SCHEMBL25356259 0.88 EGFR (0.48) DHODHEGFRBRD4KDM4EADORA2A
SCHEMBL25360145 0.87 DHODH (0.41) DHODHKDM4EALDH1A1ADORA2AADORA2B
SCHEMBL25358297 0.87 CYP2C9 (0.42) DHODHKDM4EALDH1A1MAPT
SCHEMBL30495073 0.87 CYP2C9 (0.42) DHODHKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260015341-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF HINOVA PHARMACEUTICALS INC (CN) 2026-01-15 US disclosed
EP-4553075-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2025-05-14 EP disclosed
WO-2024008122-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF 海创药业股份有限公司 2024-01-11 WO disclosed
CN-117362281-A PI3K inhibitor and preparation method and application thereof 海创药业股份有限公司 2024-01-09 CN disclosed
WO-2023159155-A1 INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF PIVALENT THERAPEUTICS, INC. (US) 2023-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260015341-A1 PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF PIK3CA, PIK3R4, PIK3R1 DHODH 1642/4885EGFR 686/4885BRD4 2130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.